As of November 2026, two treatments for painful diabetic neuropathy in the feet are genuinely new and FDA-approved: a high-strength prescription capsaicin patch (Qutenza, approved for the feet in July 2020), applied in a doctor's office every few months, and spinal cord stimulation (first approved for diabetic nerve pain in July 2021), a small implanted device for pain that medicines haven't controlled. Scrambler therapy is promising, but its studies are small and mixed. A new non-opioid pill, suzetrigine, is still in late-stage trials for neuropathy. And stem cell clinics sell treatments the FDA has not approved for chronic pain or any nerve disease.
If you've tried the usual medicines and you're still hurting, it's natural to wonder what else is out there. Search online and you'll find everything from FDA-approved devices to clinics promising to "regrow" your nerves.
This guide sorts them out. For each treatment, you'll see when it was approved (or whether it was), what the best study found, who it's for, and what to ask your doctor.
What Counts as "New"
The core treatments haven't changed much. The American Academy of Neurology's (AAN) 2022 guideline still recommends four classes of pills for painful diabetic neuropathy: SNRIs such as duloxetine, gabapentinoids such as gabapentin and pregabalin, tricyclic antidepressants, and sodium channel blockers. Our hub on treatment for neuropathy in feet covers those first steps.
What's new is mostly for people those medicines haven't helped enough. Since 2020, the FDA has approved:
- July 17, 2020: the Qutenza capsaicin 8% patch for nerve pain from diabetic neuropathy of the feet.
- July 16, 2021: the first spinal cord stimulator approved specifically for painful diabetic neuropathy (Nevro's 10 kHz system).
- 2022 to 2024: similar approvals for stimulators from Medtronic, Abbott, Boston Scientific, and Saluda Medical.
1. The Prescription Capsaicin Patch (Qutenza)
Capsaicin is the substance that makes chili peppers hot. You may know it from drugstore creams. Qutenza is a different product: a high-concentration patch that only a doctor or other healthcare professional applies and removes, according to its FDA label.
How it's done
- A single 30-minute application on the feet, using up to four patches.
- It can be repeated every three months, or when the pain comes back, but not more often than every three months.
- It goes on in the clinic, not at home. Patients are not given the patches to take home.
What the study found
In a 12-week trial of 369 people with painful diabetic neuropathy, published in The Journal of Pain in 2017, one 30-minute treatment cut average daily pain by 27.4%, compared with 20.9% for a placebo patch. Pain started improving from week 2. The authors called the relief modest, similar in size to other proven treatments, but without whole-body side effects.
Side effects to know about
- The most common, per the label: redness, pain, and itching where the patch was applied.
- The label warns that many people feel significant pain and burning during the application. Clinics usually plan for this.
- Blood pressure can rise briefly during or shortly after treatment.
- Serious burns have been reported, which is one reason only professionals apply it.
Good fit for: people whose pain is mostly in the feet, especially if pills cause too many side effects. For everyday options you can use at home, see foot creams for neuropathy.
2. Spinal Cord Stimulation
A spinal cord stimulator uses a mild electric current to block pain signals traveling up the spine, as MedlinePlus, from the U.S. National Library of Medicine, describes it. Thin wires sit near the spinal cord and connect to a small battery-powered generator under the skin.
What the main trial found
The SENZA-PDN trial, published in JAMA Neurology in 2021, enrolled 216 people with painful diabetic neuropathy that had lasted at least a year. Everyone had already tried gabapentin or pregabalin and at least one other type of pain medicine.
- At 3 months, 79% of people who got the stimulator plus their usual care had at least 50% pain relief, compared with 5% of people who stayed on usual care alone.
- In the stimulator group, average pain fell from 7.6 to 1.7 on a 10-point scale by 6 months. In the usual-care group, it barely moved (7.0 to 6.9).
- At 24 months, 90.1% of people with the device still had at least 50% pain relief.
- Infections that required removing the device happened in 2% of the stimulator group in the main study, and in 3.2% of devices over 24 months.
Two things to keep in mind. The study was open-label, meaning people knew which treatment they got, and there was no fake device for comparison. And it was run with the device maker, Nevro, some of whose staff were authors. The results are strong, but those details matter when you weigh them.
How it's done
According to MedlinePlus:
- A trial run comes first. Temporary wires are placed under numbed skin and connected to a generator you carry outside your body, like a phone. You go home the same day.
- If it greatly reduces your pain, you're offered a permanent generator a few weeks later, placed under the skin of the belly or buttocks under general anesthesia.
- Batteries: some are rechargeable. Others last 2 to 5 years and need another surgery to replace.
Risks
- Infection at the battery or wire site, which usually means removing the hardware.
- Wires that break or move, which may need another surgery.
- Spinal fluid leaks and headaches, or, rarely, nerve damage.
- The device may interfere with pacemakers and defibrillators, and you may not be able to have an MRI afterward. Ask your surgeon.
Good fit for: people whose pain stays severe after trying several medicines. MedlinePlus notes it's used after other treatments, like medicines and exercise, haven't worked.
A spinal cord stimulator is not the same as a TENS unit. TENS uses sticky pads on the skin, needs no surgery, and you can try it at home. See TENS units for neuropathy pain.
3. Scrambler Therapy
Scrambler therapy is a form of electroanalgesia, meaning pain relief through electrical signals sent through electrodes on the skin. In the trials, people received ten 30-minute sessions. It has been studied mostly in neuropathy caused by chemotherapy.
The research so far is small and mixed:
- A sham-controlled trial of 35 people (2020) found no significant difference between real and sham treatment. Some people improved during treatment, but most of the benefit faded by day 30.
- A 50-person trial comparing it with TENS (2021) found that 60% of people had at least half their symptoms relieved with scrambler therapy, compared with 25% with TENS. The difference was not statistically significant, and the authors called for a larger trial.
- A 2026 systematic review concluded that scrambler therapy "does not yet meet statistical criteria" for a successful chemotherapy neuropathy treatment, and that bigger, blinded trials are needed.
Bottom line: it may help some people, but the proof isn't there yet. If a clinic offers it, ask what results they can show and the full cost before you start. If your neuropathy came from cancer treatment, our guide to chemotherapy-induced neuropathy covers the basics.
4. In Trials: Suzetrigine, a New Non-Opioid Pill
In January 2025, the FDA approved suzetrigine (Journavx) for moderate to severe acute pain in adults, such as pain after surgery. The FDA calls it a first-in-class non-opioid that works on sodium channels in the nerves outside the brain and spinal cord, blocking pain signals before they reach the brain.
That's why researchers are testing it for diabetic nerve pain. As of November 2026, ClinicalTrials.gov lists Phase 3 trials for painful diabetic neuropathy that are still running, with main results expected in 2027. It is not approved for neuropathy. Until those results are in, nobody knows if it works for this kind of pain.
What to Be Wary Of
- Stem cell clinics. The FDA says regenerative medicine therapies, including stem cell products, have not been approved to treat chronic pain or any neurological disorder. The only FDA-approved stem cell products come from umbilical cord blood and are for blood disorders.
- "Nerve regeneration" promises. Nerves heal slowly, if at all, and no product rebuilds them on a schedule. See can you reverse neuropathy? for what recovery really looks like.
- Cure stories. A treatment that helped one person may have helped because the cause was found and fixed. Our article on "how I cured my neuropathy" stories explains what's usually behind them.
- Opioids. Not new, but still pushed. The AAN advises against them for painful diabetic neuropathy.
How to Bring This Up With Your Doctor
New treatments are usually for people who've tried the standard ones. Before your appointment, write down:
- Every medicine you've tried for nerve pain, the highest dose, and how long you took it.
- Why you stopped: it didn't help, side effects, or cost.
- Where the pain is: just the feet, or higher up the legs.
- Your pain on a 0 to 10 scale on a typical day and on a bad day.
Then ask: "Have I had a fair trial of each medicine class? Would the capsaicin patch or a spinal cord stimulator make sense for me? Who would I see for that?" If your current doctor can't answer, it may be time to see a neurologist or a pain specialist.
Talk to your doctor soon if…
- Your pain keeps you from sleeping or walking despite treatment
- You've stopped a medicine because of side effects and haven't tried another
- You're considering a clinic treatment you pay for out of pocket. Ask your doctor about it first
Get urgent care if…
- Pain, numbness, or weakness is getting worse quickly
- You notice a wound, blister, or color change on your foot that isn't healing
Frequently Asked Questions
What is the newest treatment for neuropathy in the feet?
The newest FDA-approved options for painful diabetic neuropathy in the feet are the Qutenza capsaicin 8% patch, approved for the feet in July 2020, and spinal cord stimulation, first approved for painful diabetic neuropathy in July 2021. A new non-opioid pill, suzetrigine, is in Phase 3 trials for diabetic nerve pain but is not approved for it as of November 2026.
Is the Qutenza patch the same as capsaicin cream?
No. Qutenza is a high-concentration capsaicin 8% patch that only a healthcare professional applies, in a single 30-minute session on the feet, repeated no more often than every three months. Drugstore capsaicin creams are lower strength and used regularly at home.
Does spinal cord stimulation work for diabetic neuropathy?
In the SENZA-PDN trial of 216 people whose pain had not responded to medicines, 79% of those with a 10 kHz spinal cord stimulator had at least 50% pain relief at 3 months, compared with 5% on usual care alone. The study was open-label and run with the device maker. It requires a trial period and a minor surgery, with risks such as infection.
Do stem cell treatments work for neuropathy?
There is no FDA-approved stem cell treatment for neuropathy. The FDA states that regenerative medicine therapies have not been approved to treat chronic pain or any neurological disorder, and that the only approved stem cell products come from umbilical cord blood and are used for blood disorders.
Sources
- U.S. Food and Drug Administration — Supplement Approval Letter, NDA 022395/S-019 (Qutenza, diabetic peripheral neuropathy of the feet), July 17, 2020. accessdata.fda.gov
- DailyMed — Qutenza (capsaicin) topical system, prescribing information. dailymed.nlm.nih.gov
- Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Pain, 2017;18(1):42-53. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration — Premarket Approval P130022/S039, Senza Spinal Cord Stimulation System (painful diabetic neuropathy), July 16, 2021. accessdata.fda.gov
- Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurology, 2021;78(6):687-698. pubmed.ncbi.nlm.nih.gov
- Petersen EA, Stauss TG, Scowcroft JA, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-Month results of a randomized controlled trial. Diabetes Research and Clinical Practice, 2023;203:110865. pubmed.ncbi.nlm.nih.gov
- MedlinePlus (U.S. National Library of Medicine) — Spinal Cord Stimulation. medlineplus.gov
- Smith TJ, Razzak AR, Blackford AL, et al. A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). Journal of Palliative Care, 2020;35(1):53-58. pubmed.ncbi.nlm.nih.gov
- Childs DS, Le-Rademacher JG, McMurray R, et al. Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis. Journal of Pain and Symptom Management, 2021;61(6):1247-1253. pubmed.ncbi.nlm.nih.gov
- Aldawahreh A, Etoom M, Alshraideh J, Salahat M. Efficacy of scrambler therapy in chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials. Journal of the Egyptian National Cancer Institute, 2026;38(1):6. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration — FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain, January 30, 2025. fda.gov
- ClinicalTrials.gov — Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (NCT06628908). clinicaltrials.gov
- U.S. Food and Drug Administration — Important Patient and Consumer Information About Regenerative Medicine Therapies. fda.gov
- Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology, 2022;98(1):31-43. pubmed.ncbi.nlm.nih.gov